Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk agrees to acquire Corvidia Therapeutics for $2.1bn
Under the terms of the agreement, the Danish pharmaceutical firm will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of $725m in cash. The company
Under the terms of the agreement, the Danish pharmaceutical firm will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of $725m in cash. The company
BeiGene is a commercial-stage oncology firm focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Former Amgen global commercial operations executive vice president
Under the terms of the transaction agreement, GSK has received an upfront payment of €308m ($345m) and Bavarian Nordic is expected to pay a total of up to
Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells. N6LS is an antiviral bNAb that works by
This is the first acceptance of a regulatory submission for an oral MEK 1/2 monotherapy for patients with NF1, a rare and incurable genetic condition. A Prescription Drug
Founded in 1998, Unison is an independent private equity firm investing in the healthcare sector across Japan, Korea and Singapore, with an emphasis on the pharmaceutical sector. Unison
Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs,
RedHill said that its Talicia has been indicated for oral administration in the form of delayed-release capsules in 10mg, or 250mg or in 12.5mg dosage. RedHill Biopharma chief
Horizon Therapeutics has initiated an open-label clinical trial evaluating the use of KRYSTEXXA (pegloticase injection) in adults with chronic gout refractory to conventional therapies – also known as
The trial will investigate how different doses of the compound, an inhaled epithelial sodium channel (ENaC) inhibitor, impact lung function compared to placebo when added to the standard